Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.

Onco Targets Ther · 2013 · PMC3540909 · PMID 23319867

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Progression-free survival in MET mutation-positive or unknown status patients was significantly improved, while the MET mutation-negative subgroup showed a nonsignificant trend towards improved progression-free survival with treatment, with a wide confidence interval.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.